



Food and Drug Administration
Rockville MD 20857

Re: CAMPTOSAR®
Docket No. 96E-0379

JAN 21 1997

#13

The Honorable Bruce Lehman
Assistant Secretary of Commerce and
Commissioner of Patents and Trademarks
Box Pat. Ext.
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Commissioner Lehman:

This is in regard to the application for patent term extension for U.S. Patent No. 4,604,463, filed by Kabushiki Kaisha Yakult Honsha, under 35 U.S.C. § 156 *et seq.* We have reviewed the dates contained in the application and have determined the regulatory review period for CAMPTOSAR®, the human drug product claimed by the patent.

The total length of the regulatory review period for CAMPTOSAR® is 2,111 days. Of this time, 1,941 days occurred during the testing phase and 170 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(j) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective:
September 5, 1990.

FDA has verified the applicant's claim that the date the Investigational New Drug application became effective was on September 5, 1990.

2. The date the application was initially submitted with respect to the human drug product under subsection 505(b) of the Federal Food, Drug, and Cosmetic Act: December 28, 1995.

FDA has verified the applicant's claim that the New Drug Application (NDA) for CAMPTOSAR® (NDA 20-571) was initially submitted on December 28, 1995.

3. The date the application was approved: June 14, 1996.


FDA has verified the applicant's claim that NDA 20-571 was approved on June 14, 1996.

CAMPTOSAR® - Page 2

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Stuart L. Nightingale", written in a cursive style.

Stuart L. Nightingale, M.D.
Associate Commissioner
for Health Affairs

cc: Leonard R. Svensson
Birch, Stewart, Kolash & Birch, LLP
P.O. Box 747
Falls Church, VA 22040-0747